Literature DB >> 18537968

Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia.

E Jost1, J Schmid, S Wilop, C Schubert, H Suzuki, J G Herman, R Osieka, O Galm.   

Abstract

The Wnt signalling pathway has a key function in stem cell maintenance and differentiation of haematopoietic progenitors. Secreted Frizzled-related protein genes (SFRPs), functioning as Wnt signalling antagonists, have been found to be downregulated by promoter hypermethylation in many tumours. To analyse epigenetic dysregulation of SFRPs in acute myeloid leukaemia (AML), we examined the promoter methylation status of SFRP1, -2, -4 and -5 in AML cell lines by methylation-specific polymerase chain reaction (MSP). Aberrant CpG island methylation was found for all four SFRP genes. By real-time reverse transcription-PCR, corresponding transcriptional silencing for SFRP1 and -2 was demonstrated and treatment of cell lines with 5-aza-2'-deoxycytidine resulted in re-expression. The methylation status of the SFRP genes was analysed in 100 specimens obtained from AML patients at diagnosis. The frequencies of aberrant methylation among the patient samples were 29% for SFRP1, 19% for SFRP2, 0% for SFRP4 and 9% for SFRP5. For SFRP2, a correlation between promoter hypermethylation and transcriptional downregulation was found in primary AML samples. Among AML cases with a favourable karyotype, hypermethylation of SFRP genes was restricted to patients with core binding factor (CBF) leukaemia, and aberrant methylation of the SFRP2 promoter was an adverse risk factor for survival in CBF leukaemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537968     DOI: 10.1111/j.1365-2141.2008.07242.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR.

Authors:  Rainer Claus; Stefan Wilop; Thomas Hielscher; Miriam Sonnet; Edgar Dahl; Oliver Galm; Edgar Jost; Christoph Plass
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

Review 2.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

3.  SFRP1 promoter methylation and expression in human trabecular meshwork cells.

Authors:  Weiming Mao; Jeffrey S Rubin; Nancy Anoruo; Robert J Wordinger; Abbot F Clark
Journal:  Exp Eye Res       Date:  2012-01-09       Impact factor: 3.467

Review 4.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links.

Authors:  Christina Scheel; Robert A Weinberg
Journal:  Semin Cancer Biol       Date:  2012-04-23       Impact factor: 15.707

5.  Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients.

Authors:  James B Rawson; Michael Manno; Miralem Mrkonjic; Darshana Daftary; Elizabeth Dicks; Daniel D Buchanan; H Banfield Younghusband; Patrick S Parfrey; Joanne P Young; Aaron Pollett; Roger C Green; Steven Gallinger; John R McLaughlin; Julia A Knight; Bharati Bapat
Journal:  Carcinogenesis       Date:  2011-02-08       Impact factor: 4.944

Review 6.  Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development.

Authors:  T C Luis; M Ichii; M H Brugman; P Kincade; F J T Staal
Journal:  Leukemia       Date:  2011-12-15       Impact factor: 11.528

7.  Methylation of SFRP5 is related to multidrug resistance in leukemia cells.

Authors:  H Wang; X Wang; R Hu; W Yang; A Liao; C Zhao; J Zhang; Z Liu
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

Review 8.  Role of Wnt canonical pathway in hematological malignancies.

Authors:  Xueling Ge; Xin Wang
Journal:  J Hematol Oncol       Date:  2010-09-15       Impact factor: 17.388

Review 9.  Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Clara D Bloomfield
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

10.  Decreased SFRP2 expression is associated with intermediate and poor karyotypes in de novo acute myeloid leukemia.

Authors:  Hong Guo; Jiang Lin; Xiang-Mei Wen; Jing Yang; Wei Qian; Zhao-Qun Deng; Ji-Chun Ma; Chun-Yan Tang; Cui An; Qing Liu; Hong Zhou; Jun Qian
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.